Emerging Pathogens, Vaccine and Breakthrough Infection News and Medical Cases
No significant difference in hospitalization between immunized and non-immunized found for SARS-CoV-2 Beta variant
Get link
Facebook
X
Pinterest
Email
Other Apps
A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.
About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32 (±17) days.
The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
Al-Emran HM, Hasan MS, Setu MA, Rahman MS, Alam AR, Sarkar SL, Islam MT, Islam MR, Rahman MM, Islam OK, Jahid IK. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Journal of Infection and Public Health. 2021 Dec 7.
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine. Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes. There are ten published case reports about the newly diagnosed ulcerative colitis ...
From wild type to Alpha (B.1.1.7), Delta (B.1.617.2), Omicron BA.1, BA.2, BA.5, BQ.1/BA.2.75, XBB, JN.1, FLiRT variants and now XEC and LP.8.1 (BA.2.86.1), the virus keeps evolving, continuously demonstrating its ability to adapt and mutate. As we enter the tenth wave of COVID-19 in the U.S, the XEC variant has emerged as the dominant strain - in line with expectations. It could be " a weak leading variant " but will it be a " very muted holiday wave relative to all prior years , due to weak evolution and large summer numbers"? Until recently in the US KP.3.1.1 was dominating wastewater samples and accounting for a considerable proportion of infections. Looking at the growth advantages of variants over the last year led to predictions of significantly lower impact than JN.1 that "XEC should only modestly bump what the winter wave would be without any new variant" by one of COVID forecasters . But other variants are also gaining traction. The off...
While the current SARS-COV-2 viral activity levels may seem reassuring ( back to the levels seen in October-November 2023 ), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead. From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear. The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages. In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (...
Comments
Post a Comment